Skip to content
OpenCapital
Get started

Veracyte VCYT Testing revenue — Compensation expense

Similar metrics at other companies

Encompass Health Corporation logo
EHCCompensation and benefits
$818.1M+7.3%
United Parcel Service, Inc. logo
UPSCompensation and benefits
$11.55B-2.4%
HCA Healthcare logo
HCACompensation and benefits
$8.28B+3.6%
AeroVironment logo
AVAVCompensation and benefits
$5.37M+25.7%
Quest Diagnostics logo
DGXTotal Cost of Revenue
$1.95B+9.2%
Brookfield Asset Management logo
BAMCompensation and employee benefits
$355M+37.1%

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$4.29B+10.7%

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0×0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept vcyt:CostOfRevenueCompensationExpense.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's testing revenue — compensation expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veracyte's testing revenue — compensation expense?
Veracyte (VCYT) reported testing revenue — compensation expense of $9.8M in Q1 2026.
How has Veracyte's testing revenue — compensation expense changed year-over-year?
Veracyte's testing revenue — compensation expense increased by 74.7% year-over-year, from $5.61M to $9.8M.
What is the long-term trend for Veracyte's testing revenue — compensation expense?
Over 3 years (2022 to 2025), Veracyte's testing revenue — compensation expense has grown at a 13.1% compound annual growth rate (CAGR), from $17.02M to $24.61M.
What does testing revenue — compensation expense mean?
This represents the direct personnel costs, including salaries and benefits, for staff specifically dedicated to the laboratory testing and diagnostic operations. It provides insight into the labor intensity required to maintain testing throughput.